MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin.

Trial Profile

MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms MAGELLAN
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 30 Aug 2017 Results of pooled data from four randomized trials (EXCLAIM, ADOPT, MAGELLAN, and APEX trials) assessing qualitatively and quantitatively risk-benefit profile of extended-duration pharmacologic prophylaxis using the bivariate analysis, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 07 Feb 2013 Results published in the New England Journal of Medicine.
    • 03 Jul 2012 Company added in the association field as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top